130 related articles for article (PubMed ID: 33258301)
1. Validating impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
Atallah S; Le LW; Bezjak A; MacRae R; Hope AJ; Pantarotto J
Thorac Cancer; 2021 Jan; 12(2):201-209. PubMed ID: 33258301
[TBL] [Abstract][Full Text] [Related]
2. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
Ostheimer C; Mäurer M; Ebert N; Schmitt D; Krug D; Baumann R; Henkenberens C; Giordano FA; Sautter L; López G; Fleischmann DF; Niyazi M; Käsmann L; Kaul D; Thieme AH; Billiet C; Dobiasch S; Arnold CR; Oertel M; Haussmann J; Gauer T; Goy Y; Suess C; Ziegler S; Panje CM; Baues C; Trommer M; Skripcak T; Medenwald D
Strahlenther Onkol; 2021 May; 197(5):385-395. PubMed ID: 33410959
[TBL] [Abstract][Full Text] [Related]
4. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
5. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
[TBL] [Abstract][Full Text] [Related]
8. The impact of histology in the outcomes of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) and adjuvant chemotherapy.
Ernani V; Appiah AK; Baine MJ; Smith LM; Ganti AK
Cancer Treat Res Commun; 2020; 24():100197. PubMed ID: 32777751
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for stage I non-small cell lung cancer: The importance of treatment planning algorithm and evaluation of a tumor control probability model.
Ohri N; Tomé W; Kalnicki S; Garg M
Pract Radiat Oncol; 2018; 8(2):e33-e39. PubMed ID: 29233523
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
Ager BJ; Wells SM; Gruhl JD; Stoddard GJ; Tao R; Kokeny KE; Hitchcock YJ
Lung Cancer; 2019 Dec; 138():6-12. PubMed ID: 31593894
[TBL] [Abstract][Full Text] [Related]
11. Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance.
Spratt DE; Wu AJ; Adeseye V; Din SU; Shaikh F; Woo KM; Zhang Z; Foster A; Rosenzweig KE; Gewanter R; Huang J; Rimner A
Clin Lung Cancer; 2016 May; 17(3):177-183.e2. PubMed ID: 26602271
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.
Trovo M; Minatel E; Durofil E; Polesel J; Avanzo M; Baresic T; Bearz A; Del Conte A; Franchin G; Gobitti C; Rumeileh IA; Trovo MG
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1114-9. PubMed ID: 24661664
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations.
Agarwal JP; Pilar A; Mummudi N; Gupta M; Laskar SG; Pathak RS; Tibdewal AR; Kinhikar R; Ghadi Y; Tandon S; Purandare N; Prabhash K; Patil V
Indian J Cancer; 2020; 57(1):18-24. PubMed ID: 31929233
[TBL] [Abstract][Full Text] [Related]
15. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
Tan D; Gill S; Loh N
Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
17. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
18. Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions.
Bousabarah K; Blanck O; Temming S; Wilhelm ML; Hoevels M; Baus WW; Ruess D; Visser-Vandewalle V; Ruge MI; Treuer H; Kocher M
Radiat Oncol; 2021 Apr; 16(1):74. PubMed ID: 33863358
[TBL] [Abstract][Full Text] [Related]
19. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
20. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
